WO2019246408A2 - Immunothérapie à base de peptide lié à un anticorps pour le diabète de type 1 - Google Patents

Immunothérapie à base de peptide lié à un anticorps pour le diabète de type 1 Download PDF

Info

Publication number
WO2019246408A2
WO2019246408A2 PCT/US2019/038264 US2019038264W WO2019246408A2 WO 2019246408 A2 WO2019246408 A2 WO 2019246408A2 US 2019038264 W US2019038264 W US 2019038264W WO 2019246408 A2 WO2019246408 A2 WO 2019246408A2
Authority
WO
WIPO (PCT)
Prior art keywords
insulin
chromogranin
composition
peptide
antigen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2019/038264
Other languages
English (en)
Other versions
WO2019246408A3 (fr
Inventor
Matthew Louis BETTINI
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Baylor College of Medicine
Original Assignee
Baylor College of Medicine
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Baylor College of Medicine filed Critical Baylor College of Medicine
Publication of WO2019246408A2 publication Critical patent/WO2019246408A2/fr
Publication of WO2019246408A3 publication Critical patent/WO2019246408A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6813—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin the drug being a peptidic cytokine, e.g. an interleukin or interferon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/19—Dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
    • A61K40/22—Immunosuppressive or immunotolerising
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
    • A61K40/24—Antigen-presenting cells [APC]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/416—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/62—Insulins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2851—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies

Definitions

  • Embodiments of the disclosure include at least the fields of molecular biology, cell biology, immunology, and medicine.
  • tissue-specific antigens are presented by autoimmune regulator (Aire) and Fezf2 expressing thymic medullary epithelial cells (mTECs) to aide in the deletion of self-reactive thymocytes (1, 2).
  • TSAs tissue-specific antigens
  • mTECs thymic medullary epithelial cells
  • DCs thymic resident dendritic cells
  • Dendritic cells and Aire expressing mTECs are also essential in generating thymically derived Foxp3+ regulatory T cells (Tregs) and promoting self tolerance (4, 5). Indeed, there appears to be a correlation between a reduction in dendritic cell (DC) numbers and residual b cell function in Type 1 diabetic (T1D) subjects (6), while in the NOD mouse there is an overall reduction in dendritic cells (7, 8), suggesting a relationship between self-tolerance and the absolute number of DCs present in the thymus and periphery.
  • DC dendritic cell
  • T1D Type 1 diabetic
  • Chromogranin A is the only other currently known b cell antigen necessary for the initiation of autoimmune diabetes in the NOD mice; however, expression within mTECs has not yet been detected (10). Therefore, tolerance to ChgA may be due in part to peripheral dendritic cells presenting ChgA to developing and naive T cells.
  • PTMs post-translationally modified peptides
  • Neo-antigen expression in b cells The mechanisms behind the break in tolerance to self, allowing for the development of autoimmune diseases, appear to be multifaceted and poorly understood (10-12). Because of the demand on insulin producing b cells, oxidative and ER stress appear to be contributing factors in the initiation of TlD (l3, 14). A consequence of cellular stress is the altered processing of proteins, such as changes in post-translational modifications (PTMs) by deamidation or proteolytic transpeptidation, which can lead to generation of tissue specific neo-antigens (15-18). Pathogenic T cells that are specific for neo antigens uniquely expressed in the pancreas may escape thymic selection by a process known as ignorance (19).
  • PTMs post-translational modifications
  • John Kappler's group showed that a mimotope of the lnsB9_ 2 3 insulin peptide with a change in the MHC anchor residue (R22E) was highly stimulatory for insulin reactive T cells and was used to generate MHC:peptide tetramers to track this cells in vivo (22).
  • Kathryn Haskins' group demonstrated that PTMs allow for the formation of neo-antigens by fusion of the pro-insulin peptide with other peptides within b cells granules (23).
  • Dr. Eddie James has shown that T cells specific for deamidated PTM b cell antigens are present at higher frequencies in T1D patients (17, 24).
  • Tgase2 tissue transglutaminase 2
  • PTM peptide bearing APCs can influence the development of autoreactive T cells and protective T regulatory cells.
  • vaccine strategies that will halt the initiation and development of autoimmune Type 1 diabetes.
  • the present disclosure is directed to compositions, systems, and methods that prevent or delay the onset of one or more autoimmune diseases in an individual having, or at risk of having, an autoimmune disease.
  • the individual may have, or be at risk of having, Type 1 diabetes, multiple sclerosis, rheumatoid arthritis, systemic lupus erythematosus, celiac sprue disease, pernicious anemia, vitiligo, scleroderma, psoriasis, Inflammatory bowel diseases, Addison’s Disease, Graves’ Disease, Sjogren’s syndrome, or any other autoimmune disease, or a combination thereof.
  • the individual may be of any age, such as an individual in utero, a neonatal individual, a pre-pubescent individual, a pubescent individual, or an adult.
  • Some embodiments of the disclosure concern methods that are suitable for ameliorating one of more symptoms arising from the autoimmune disease, the cause of the autoimmune disease, or both.
  • Some embodiments concern one or more compositions that may include (1) cellular therapies, such as native or modified cells; and/or (2) immunotherapies, such as antibodies or peptide-linked antibodies, for example.
  • the compositions may target immune cells, such as dendritic cells and/or FoxP3 + cells, for example.
  • T cells lacking the ability to recognize “self’ antigens. These T cells then attack and destroy“self’ cells in an individual, such as the individual having, or at risk of having, an autoimmune disease. At least some methods of the present disclosure may decrease the T cells that lack“self’ recognition. Decreasing these cells may ameliorate one or more symptoms and/or one or more causes of autoimmune diseases. The methods may also increase certain types of cells, including regulatory T (T reg )cells, that regulate autoimmunity. Increasing T reg cells may ameliorate one or more symptoms and/or one or more causes of one or more autoimmune diseases.
  • T reg regulatory T
  • compositions are administered to an individual having, or at risk of having, an autoimmune disease.
  • the composition may comprise one or more types of cells, such as dendritic cells or FoxP3 + cells, and/or one or more types of compositions that can target immune cells in the individual.
  • the composition may comprise an antibody or a conjugated antibody.
  • the antibody either alone or conjugated, may target any antigen or cell, such as an antigen or cell that is involved in autoimmunity, including directly or indirectly related to autoimmunity.
  • the conjugated antibody may comprise an antibody that is conjugated to another molecule, such as a peptide, lipid, nucleic acid, small molecule, or any other molecule.
  • the molecule conjugated to the antibody may be useful for T cell antigen recognition, including modifying T cell“self’ antigen recognition.
  • the antibody and molecule conjugated to the antibody may be linked in any manner, including a non-covalent assembly system such as a dockerin/ cohesin system.
  • the composition that is administered to the individual may comprise one or more cells, including one or more types of cells.
  • the cell may be of any cell type, including an immune cell and/or antigen presenting cells, such as a dendritic cell.
  • the cell may be manipulated or cultured in a manner to improve the ability of the cell to present an antigen.
  • the cell may present any antigen, including“self’ antigens that are pathologically recognized in autoimmune diseases.
  • the presentation of the antigen by the cell of the composition may lead to a decrease in pathogenic immune cells.
  • the presentation of the antigen by the cell of the composition may lead to an increase in T reg cells.
  • Embodiments of the disclosure include compositions comprising:(a) an antibody, wherein said antibody targets dendritic cells and/or Foxp3+ cells; linked to (b) a peptide or fusion of peptides, wherein said peptide(s) is (are) a pancreatic beta cell antigen(s) or is an autoimmune antigen-derived peptide(s).
  • the antibody targets Langerin, DEC-205, Interleukin 2 (IL2) Receptor, CD25, CD 122, or CLEC9A.
  • the peptide or fusion of peptides comprise one or more peptides derived from insulin, IL2, chromogranin A, glutamic acid decarboxylase 65 (GAD-65), IA-2, ZnT8, ICA69, IGRP, myelin oligodendrocyte glycoprotein (MOG), neurofilament NF-M, myelin basic protein (MBP), proteolipid protein (PLP), myelin-associated antigen (MAG), myelin-associated oligodendrocyte basic protein (MOBP), SlOOp, CNPase, Transaldolase, collagen basement membrane type IV, ANA, SMA, LKM-l, LKM-2, LKM-3, SLA, p62,spl00, M2, SSA, HLA-DR52a, BP-l, BP-2, IL-2, IFN-gamma, COL7A1, desmoglein-3, NALP-l RER, PTPN22,
  • the peptide may be a hybrid insulin/chromogranin A fusion peptide, such as a hybrid insulin/chromogranin A fusion peptide being 2.5HIP.
  • the peptide comprises Insulin B:9-23, Insulin B:9-23 (R22E), Chromogranin A (2.5HIP), or Chromogranin A (WE14).
  • the autoimmune antigen-derived peptide is Insulin B:9-23, Insulin B:9-23 (R22E), Chromogranin A (2.5HIP), Chromogranin A (WE 14), or functional variants having at least 80, 85, 90, 95, 96, 97, 98, or 99% identity thereof.
  • the composition may comprise a mixture of non-identical compositions.
  • the mixture comprises (a) a first composition comprising an antibody that targets Langerin linked to a hybrid insulin/chromogranin A fusion peptide, and (b) a second composition comprising an antibody that targets Langerin linked to an IL2 peptide.
  • the mixture comprises (a) a first composition comprising an antibody that targets Langerin linked to a hybrid insulin/chromogranin A fusion peptide, and (b) an antibody that targets IL-2 receptor linked to an IL2 peptide.
  • the mixture comprises (a) a first composition comprising an antibody that targets Langerin linked to a hybrid insulin/chromogranin A fusion peptide, and (b) an antibody that targets CD25 linked to IL2 peptide and (c) an antibody that targets CD 122 linked to IL2 peptide.
  • the antibody and the peptide(s) are linked by a non-covalent assembly system, such as dockerin/ cohesin.
  • compositions comprising an immune cell, wherein the immune cell presents at least one antigen, wherein the immune cell is modified to present the one or more antigens, wherein the one or more antigens comprise an antigen derived from IL2, chromogranin A, collagen basement membrane type IV, ANA, SMA, LKM-l, LKM- 2, LKM-3, SLA, p62,spl00, M2, SSA, HLA-DR52a, BP-l, BP-2, IL-2, IFN-gamma, COL7A1, desmoglein-3, NALP-l RER, PTPN22, LPP, IL2RA, GXMB, UBASH3A, C1QTNF6,
  • the antigen presented may comprise Insulin B:9-23, Insulin B:9-23 (R22E), Chromogranin A (2.5HIP), or Chromogranin A (WE 14).
  • the antigen presented may comprise Insulin B:9-23, Insulin B:9-23 (R22E), Chromogranin A (2.5HIP), or Chromogranin A (WE 14) or functional variants having at least 80, 85, 90, 95, 96, 97, 98, or 99% identity thereof.
  • there is a method of preventing or delaying onset of an autoimmune disease in an individual comprising the step of providing to the individual an effective amount of one or more of the compositions encompassed by the disclosure.
  • the individual may be in utero, is a newborn, is an infant, is a child, is an adolescent, or is an adult.
  • the composition may be administered topically, intravenously, or intraperitoneally, including by injection.
  • the autoimmune disease is Type 1 Diabetes, rheumatoid arthritis, systemic lupus erythematosus, celiac sprue disease, pernicious anemia, vitiligo, scleroderma, psoriasis, inflammatory bowel diseases, Addison’s Disease, Graves’ Disease, or Sjogren’s syndrome.
  • the autoimmune disease may comprise the recognition of one or more antigens, wherein the one or more antigens comprise an antigen derived from insulin, IL2, chromogranin A, glutamic acid decarboxylase 65 (GAD-65), IA-2, ZnT8, ICA69, IGRP, myelin
  • oligodendrocyte glycoprotein MOG
  • MBP myelin basic protein
  • PBP proteolipid protein
  • MAG myelin-associated antigen
  • MOBP myelin-associated oligodendrocyte basic protein
  • SlOOp CNPase, Transaldolase, collagen basement membrane type IV, ANA, SMA, LKM-l, LKM-2, LKM-3, SLA, p62,spl00, M2, SSA, HLA-DR52a, BP-l, BP-2, IL-2, IFN-gamma, COL7A1, desmoglein-3, NALP-l RER, PTPN22, LPP, IL2RA, GXMB, UBASH3A, C1QTNF6, HLADR5, CTLA-4, TSHR, AD AMTS 13, HPA-la, HPA-5b, MMP3, vimentin, MCV, IgGFc, ANCA, Clq, or a combination
  • the autoimmune disease comprises the recognition of one or more antigens, wherein the one or more antigens comprise Insulin B:9-23, Insulin B:9-23 (R22E), Chromogranin A (2.5HIP), Chromogranin A (WE 14), or a combination thereof.
  • the autoimmune disease may comprise the recognition of one or more antigens, wherein the one or more antigens comprise a functional variant comprising 80, 85, 90, 95, 96, 97, 98, or 99% identity to Insulin B:9-23, Insulin B:9-23 (R22E),
  • Chromogranin A (2.5HIP), Chromogranin A (WE 14), or a combination thereof.
  • the antibody targets Langerin, DEC-205, Interleukin 2 (IL2) Receptor, CD25, CD 122, or CLEC9A.
  • the peptide comprises Insulin B:9-23, Insulin B:9-23 (R22E), Chromogranin A (2.5HIP), or Chromogranin A (WE14).
  • the individual may be a neonate, and the cell may comprise an antigen derived from insulin.
  • the antigen comprises Insulin B:9-23, Insulin B:9-23 (R22E), or both.
  • FIG. 1 shows targeting of thymic antigen presenting cells to enhance tolerance to AIRE-independent antigens.
  • Adult NOD WT mice were intraperitoneal injected once with 3.0ug of anti-Langerin APC. At indicated time points, thymus was harvested and co-stained with anti- langerin PE to determine binding efficiency and persistence within the thymus over time.
  • FIG. 2 demonstrates that a-Langerin-2.5HIP treatment induces thymic Treg development and deletion in Adult BDC2.5 TCR Tg Mice.
  • Adult TCR transgenic BDC2.5 NOD T Cell Receptor is specific for 2.5HIP mice were intraperitoneal injected once with 10.0 pg of a-Langerin-2.5HIP. After 48 hours, thymus was harvested and thymocyte cellularity and maturation markers were analyzed.
  • Administration of 2.5HIP depletes immature CD4+CD8+ Double positive (DP) thymocytes, however, there is no change in the more mature CD4+ single positive (SP) population.
  • FIG. 1 TCR transgenic BDC2.5 NOD mice were intraperitoneal injected once with 10.0 pg of a-Langerin-2.5HIP. After 48 hours, thymus was harvested and thymocyte cellularity and maturation markers were analyzed.
  • Administration of 2.5HIP depletes immature CD4+CD8
  • FIG. 3 shows that a-Langerin-2.5HIP treatment induces thymic Treg development and deletion in Adult BDC2.5 TCR Tg Mice.
  • Adult TCR transgenic BDC2.5 NOD were intraperitoneal injected once with 10.0 pg of a-Langerin-2.5HIP. After 48 hours, thymus was harvested and the Foxp3+ T Regulatory cell (Tregs) population was assessed.
  • Tregs Foxp3+ T Regulatory cell
  • FIGS. 4A-4B provide that a-Langerin-2.5HIP treatment induces neonatal thymic Treg development.
  • Day 1-3 Neonatal BDC2.5 TCR transgenic mice were intraperitoneal injected once with 5 pg anti-langerin alone, 2.5ug a-Langerin-2.5HIP or 5 pg anti- langerin/2.5HIP .
  • Bottom left It appears 5 pg of a-Langerin-2.5HIP does not induce dramatic CD4+CD8+ DP reduction like adult mice with 10 pg.
  • (right side) After 48 hours, CD4 SP Foxp3+ Treg development was assessed and significant increase is observed.
  • FIG. 5 demonstrates that a-Langerin-2.5HIP treatment induces differential CD25 expression on thymic Tregs.
  • FIG. 6 shows a-Langerin-2.5HIP treatment induces differential CD25 expression on thymic Tregs.
  • Day 1-3 Neonatal BDC2.5 TCR transgenic mice were intraperitoneal injected once with 2.5 pg a-Langerin-2.5HIP.“New” Foxp3 Tregs are not CD25+, however normal levels of Helios (top right), a thymically derived Treg marker, but low for Nrpl (bottom right), a peripheral marker for non-gut derived Tregs.
  • FIG. 7 illustrates CD122 and CD25 expression on Foxp3+ cells. Day 1-3
  • Neonatal BDC2.5 TCR Transgenic mice were intraperitoneal injected once with 2.5 pg a- Langerin-2.5HIP.“New” Foxp3 Tregs are express intermediate levels of CD 122 (green shaded box and histogram), which is part of the low affinity IL-2 receptor.
  • FIG. 8 illustrates selective T cell subset potentiation with IL-2 antibodies.
  • CD25 is highly expressed on mature, functional Tregs.
  • FIG. 9 demonstrates an effect of Anti-Langerin-2.5HIP IL-2 combination on Foxp3+ thymocyte development.
  • HI and LO IL-2 complexes are antibodies targeting IL-2.
  • the JES6-IA12 antibody (HI) recognizes the high affinity IL-2 receptor chain CD25, while JES6- IA12 antibody (LO) recognized the low affinity IL-2 receptor chain CD122.
  • IL-2 By linking active IL-2 to either JES6-IA12 or JES6-IA12 antibody, IL-2 can be targeted to CD25+ and/or CD122+ expressing Foxp-i- Tregs.
  • Two-day old neonatal mice were given either Anti-langerin-2.5HIP or a combination of Anti-langerin and IL-2 (HI) or a 1: 1 ratio of HI and LO-IL-2 complex.
  • FIG. 10 provides that a-Langerin-2.5HIP with IL-2 complex promotes thymocyte survival.
  • Day 2 Neonatal BDC2.5 TCR transgenic mice were intraperitoneal injected once with anti-langerin alone, 2.5ug a-Langerin-2.5HIP, or with anti-Langerin bound to active human IL-2 (middle), or co-injected with mouse IL-2 bound to anti-CD25 (second from right) or anti-CD 122 and anti-CD25 (far right).
  • IL-2 treatment with a-Langerin-2.5HIP treatment stabilizes
  • CD4+CD8+ thymocyte development CD4+CD8+ thymocyte development.
  • FIG. 11 shows that a-Langerin-2.5HIP with IL-2 complex promotes Treg development.
  • Day 2 Neonatal BDC2.5 TCR transgenic mice were intraperitoneal injected once with anti-langerin alone, 2.5 pg a-Langerin-2.5HIP, or with anti-Langerin bound to active human IL-2 (middle), or co-injected with mouse IL-2 bound to anti-CD25 (second from right) or anti- CD 122 and anti-CD25 (far right).
  • IL-2 treatment with a-Langerin-2.5HIP treatment dramatically increases Tregs development.
  • FIG. 12 demonstrates that a-Langerin-2.5HIP with IL-2 complex does not lead to CD25 expression.
  • Day 2 Neonatal BDC2.5 TCR transgenic mice were intraperitoneal injected once with anti-langerin alone, 2.5 pg a-Langerin-2.5HIP, or with anti-Langerin bound to active human IL-2 (middle), or co-injected with mouse IL-2 bound to anti-CD25 (second from right) or anti-CDl22 and anti-CD25 (far right).
  • IL-2 treatment with a-Langerin-2.5HIP DOES NOT rescue CD25 expression on“new” Foxp3+ Tregs.
  • FIG. 13 demonstrates indication of protection/delay in developing Type I Diabetes. 1-2 day old NOD WT female pups were injected with anti-langerin alone or a- Langerin-2.5HIP. Diabetes incidence were monitored weekly by Diastix and confirmed by blood glucose level. Diabetes is defined as blood glucose level of >300 mg/dl for 2 consecutive days or >400 mg/dl at the first reading.
  • FIG. 14 shows that Foxp3+ Tregs are not killed by antibody treatment as indicate by cleaved (active) Caspase3 staining. Day 2 Neonatal BDC2.5 TCR transgenic mice were intraperitoneal injected once with 2.5 pg anti-langerin alone, 2.5 pg a-Langerin-2.5HIP, or DPBS. a-Langerin-2.5HIP or anti-langerin alone does not kill“new” Foxp3+ Tregs.
  • FIG. 15 shows Ab-2.5HIP-generated Foxp3+ cells are almost entirely CD73- (thymically derived).
  • Day 2 Neonatal BDC2.5 TCR transgenic mice were intraperitoneal injected once with 2.5 pg anti-langerin alone, 2.5 pg a-Langerin-2.5HIP, or DPBS. Lack of CD73 expression indicates thymically derived Tregs. Peripheral Tregs that circulate back to the thymus are CD73+.
  • the term “about” or “approximately” refers to a quantity, level, value, number, frequency, percentage, dimension, size, amount, weight or length that varies by as much as 30, 25, 20, 25, 10, 9, 8, 7, 6, 5, 4, 3, 2 or 1 % to a reference quantity, level, value, number, frequency, percentage, dimension, size, amount, weight or length.
  • the terms “about” or “approximately” when preceding a numerical value indicates the value plus or minus a range of 15%, 10%, 5%, or 1 %.
  • the term can mean within an order of magnitude, preferably within 5-fold, and more preferably within 2-fold, of a value. Unless otherwise stated, the term 'about' means within an acceptable error range for the particular value.
  • administering refers to any method of providing a composition to an individual such that the composition has its intended effect on the patient.
  • one method of administering is by an indirect mechanism using a medical device such as, but not limited to a catheter, applicator gun, syringe etc.
  • a second exemplary method of administering is by a direct mechanism such as, local tissue administration, oral ingestion, transdermal patch, topical, inhalation, suppository etc.
  • the term“antigen” describes any molecule that is recognized by immune cells or immune molecules, such as an antibody.
  • the term may refer to any small molecule or macromolecule, such as a nucleic acid of any length, a peptide of any length, a lipid of any length, or a combination thereof.
  • the term may include peptides derived from proteins that are present in an individual.
  • the antigen may be any peptide derived from any protein described in the disclosure, or any natural or functionally equivalent variant of any protein described in the disclosure, including variants differing by 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or more amino acids.
  • the natural or functional variants may also have conservative mutations at any site.
  • Conservative mutations may be a change of one amino acid to any other amino acid in the group consisting of Gly, Ala, Val, Leu, Ile; or the group consisting of Ser, Cys, Selenomethionine, Thr, Met; or the group consisting of Phe, Tyr, Trp; or the group consisting of His, Lys, Arg; or the group consisting of Asp, Glu, Asn, Gln.
  • the antigens may have insertions or deletions from the naturally occurring antigen, such as insertions or deletions of 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or more amino acids.
  • the antigen may be a fusion of two or more proteins, or any fragment of the fusion of two or more proteins.
  • the antigen may be recognized by compositions of the disclosure.
  • the antigen may comprise part or all of the compositions of the disclosure. In specific cases, the antigen is an autoantigen (an antigen that is a normal constituent of an individual and against which the immune system produces autoantibodies).
  • the term "individual”, as used herein, refers to a human or animal that may or may not be housed in a medical facility and may be treated as an outpatient of a medical facility. The individual may be receiving one or more medical compositions via the internet.
  • An individual may comprise any age of a human or non-human animal and therefore includes both adult and juveniles ( i.e ., children) and infants. It is not intended that the term "individual” connote a need for medical treatment, therefore, an individual may voluntarily or involuntarily be part of experimentation whether clinical or in support of basic science studies.
  • subject refers to any organism or animal subject that is an object of a method or material, including mammals, e.g., humans, laboratory animals (e.g., primates, rats, mice, rabbits), livestock (e.g., cows, sheep, goats, pigs, turkeys, and chickens), household pets (e.g., dogs, cats, and rodents), horses, and transgenic non-human animals.
  • mammals e.g., humans, laboratory animals (e.g., primates, rats, mice, rabbits), livestock (e.g., cows, sheep, goats, pigs, turkeys, and chickens), household pets (e.g., dogs, cats, and rodents), horses, and transgenic non-human animals.
  • livestock e.g., cows, sheep, goats, pigs, turkeys, and chickens
  • household pets e.g., dogs, cats, and rodents
  • horses e.g., dogs, cats, and rodents
  • transgenic non-human animals
  • the term“peptide” refers to a polypeptide chain of amino acids.
  • the peptide is between 9-21 amino acids in length, in some cases between 10-20 amino acids in length, in some cases between 11-20 amino acids in length.
  • the peptide is derived from a protein.
  • the peptide may be any polypeptide chain from the protein.
  • Some embodiments of the present disclosure concern multiple peptides, including multiple peptides derived from the same protein. In such embodiments, a peptide may overlap with a different peptide derived from the same protein.
  • the overlapping peptides have one or more amino acids that overlap, such as 1-10, 1-9, 1-8, 10-7, 1- 6, 1-5, 1-4, 1-3, or 1-2 amino acids that overlap.
  • the term“self’ in the context of protein, antigens, cells, or the like;“self-cell”; or“self-antigen” refer to proteins, antigens, cells, or the like that originate from an individual that has, or is at risk of having, an autoimmune disease. These“self’ molecules are endogenous to the individual and may be pathologically recognized by immune cells of the individual.
  • an effective amount is synonymous with “effective amount”, “therapeutically effective dose”, and/or “effective dose” and refers to the amount of compound that will elicit the biological, cosmetic or clinical response being sought by the practitioner in an individual in need thereof.
  • an effective amount is the amount sufficient to reduce immunogenicity of a group of cells.
  • an effective amount is an amount sufficient to promote formation of a blood supply sufficient to support the transplanted tissue.
  • an effective amount is an amount sufficient to promote formation of new blood vessels and associated vasculature
  • angiogenesis angiogenesis and/or an amount sufficient to promote repair or remodeling of existing blood vessels and associated vasculature.
  • the appropriate effective amount to be administered for a particular application of the disclosed methods can be determined by those skilled in the art, using the guidance provided herein. For example, an effective amount can be extrapolated from in vitro and in vivo assays as described in the present specification. One skilled in the art will recognize that the condition of the individual can be monitored throughout the course of therapy and that the effective amount of a compound or composition disclosed herein that is administered can be adjusted accordingly.
  • Treatment means a method of reducing the effects of a disease or condition.
  • Treatment can also refer to a method of reducing the disease or condition itself rather than just the symptoms.
  • the treatment can be any reduction from pre-treatment levels and can be but is not limited to the complete ablation of the disease, condition, or the symptoms of the disease or condition. Therefore, in the disclosed methods, treatment” can refer to a 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, or 100% reduction in the severity of an established disease or the disease progression, including reduction in the severity of at least one symptom of the disease.
  • a disclosed method for reducing the immunogenicity of cells is considered to be a treatment if there is a detectable reduction in the immunogenicity of cells when compared to pre-treatment levels in the same subject or control subjects.
  • the reduction can be a 10, 20, 30, 40, 50, 60, 70, 80, 90, 100%, or any amount of reduction in between as compared to native or control levels.
  • treatment does not necessarily refer to a cure of the disease or condition, but an improvement in the outlook of a disease or condition.
  • treatment refers to the lessening in severity or extent of at least one symptom.
  • Autoimmune diseases are thought to arise from immune cells in an individual pathologically recognizing self-antigens as foreign antigens, thus triggering an immune response against self-cells.
  • self-antigens In an individual that does not have an autoimmune disease, there are mechanisms and immune cells, such as dendritic cells and regulatory T (T reg ) cells that allow for self-tolerance. In autoimmune diseases these mechanisms and immune cells may malfunction.
  • T reg regulatory T
  • Type 1 diabetes arises from the pathological recognition of self-antigens present on b cells of the pancreas.
  • autoimmune diseases include, but are not limited to, multiple sclerosis, rheumatoid arthritis, systemic lupus erythematosus, celiac sprue disease, pernicious anemia, vitiligo, scleroderma, psoriasis, inflammatory bowel diseases, Addison’s Disease, Graves’ Disease, or Sjogren’s syndrome.
  • Embodiments of the disclosure concern methods of reducing the immune system pathological recognition of self-antigens.
  • the self-antigen may be any antigen, including those that may trigger autoimmune reactions.
  • the self-antigen may be expressed on any self-cell in an individual having, or at risk of having, an autoimmune disease.
  • Embodiments of the methods of the disclosure decrease the recognition of self antigens by pathogenic immune cells, including pathogenic T cells.
  • the methods in specific aspects increase the recognition of self-antigens by regulatory and/or anti-inflammatory immune cells.
  • the self-antigens may be derived from one or more of the following: insulin, IL2, chromogranin A, glutamic acid decarboxylase 65 (GAD-65), IA-2, ZnT8, ICA69, IGRP, myelin oligodendrocyte glycoprotein (MOG), neurofilament NF-M, myelin basic protein (MBP), proteolipid protein (PLP), myelin-associated antigen (MAG), myelin-associated oligodendrocyte basic protein (MOBP), SlOOp, CNPase, Transaldolase, collagen basement membrane type IV, ANA, SMA, LKM-l, LKM-2, LKM-3, SLA, p62,spl00, M2, SSA,
  • Decreasing pathogenic immune cells, including those that recognize self-antigens, and increasing regulatory immune cells, including those that recognize self-antigens, may alter the pathogenesis of certain autoimmune diseases. Altering the pathogenesis of one or more autoimmune diseases may lead to an increase of the self-cells that were targeted by pathogenic immune cells. Increasing the number of self cells that were targeted by immune cells may restore function that was lost due to the autoimmune disease.
  • Embodiments of the disclosure concern compositions, such as a cell and/or a molecule (including bipartite molecules comprising an antibody linked to a peptide), that regulate autoimmunity.
  • the composition comprises at least one cell, such as an immune cell or antigen presenting cell.
  • the cell may present one or more antigens that are involved in the pathogenesis of an autoimmune disease.
  • the cell may present the antigen endogenously or may be manipulated to present the antigen.
  • the cell may be incubated with a single peptide or a mixture different pulsed with peptides from the antigen involved in autoimmunity.
  • the cell may also be manipulated to exogenously express and present the antigen.
  • the antigen is a fragment from the protein and/or peptide selected from the group consisting of insulin, IL2, chromogranin A, glutamic acid decarboxylase 65 (GAD-65), IA-2, ZnT8, ICA69, IGRP, myelin oligodendrocyte glycoprotein (MOG), neurofilament NF-M, myelin basic protein (MBP), proteolipid protein (PLP), myelin-associated antigen (MAG), myelin-associated oligodendrocyte basic protein (MOBP), SlOOp, CNPase, Transaldolase, collagen basement membrane type IV, ANA, SMA, LKM-l, LKM-2, LKM-3, SLA, p62,spl00, M2, SSA, HLA-DR52a, BP-l, BP-2, IL-2, IFN-gamma,
  • the antigen may be any fragment of the listed proteins and/or peptides, or a fragment of any functional and/or natural variant of the listed proteins and/or peptides.
  • the functional variant may have at least 80, 85, 90, 95, 96, 97, 98, or 99% identity thereof.
  • the antigen may be a fusion of peptides derived from two or more proteins, including the proteins disclosed herein.
  • Cells of the present disclosure can be isolated from any source, including allogeneic and autologous sources.
  • antigen presenting cells such as dendritic cells
  • Dendritic cells may be isolated from blood or other leukocytes using known methods in the art.
  • antigen presenting cells including dendritic cells for example, are generated from other cell types, such as monocytes for example.
  • the cells may be cultured using any known culture methods known in the art.
  • the cells are manipulated to increase the presentation of one or more antigens that are involved in autoimmune diseases. Any known method may be used to increase the presentation of one or more antigens disclosed herein.
  • the antigen presented by the cell may be at least one of the antigens selected from the group consisting of insulin, IL2, chromogranin A, glutamic acid decarboxylase 65 (GAD-65), IA-2, ZnT8, ICA69, IGRP, myelin oligodendrocyte glycoprotein (MOG), neurofilament NF-M, myelin basic protein (MBP), proteolipid protein (PLP), myelin-associated antigen (MAG), myelin-associated oligodendrocyte basic protein (MOBP), SlOOp, CNPase, Transaldolase, collagen basement membrane type IV, ANA, SMA, LKM-l, LKM-2, LKM-3, SLA, p62,spl00, M2, SSA, HLA-DR52a, BP-l, BP-2, IL-2, IFN- gamma, COL7A1, desmoglein-3, NALP-l RER, PTPN22, LPP
  • the antigen presented by the cell may be any peptide fragment from insulin, including insulin B:9-23, insulin B:9-23 (R22E).
  • the antigen presented by the cell may be any peptide fragment of chromogranin A, including WE 14.
  • the antigen presented by the cell may be any fragment of a fusion between two or more proteins, such as the peptide 2.5HIP.
  • the antigen presented by the cell may be any functional or natural variant of the antigens described herein.
  • the functional variant may have at least 80, 85, 90, 95, 96, 97, 98, or 99% identity thereof.
  • the composition comprises at least one molecule, such as an antibody.
  • the molecule comprises an antibody.
  • the antibody may recognize any antigen on one or more self-cells, such as a self-cell that is involved in one or more autoimmune diseases.
  • the antibody may recognize antigens present on immune cells such as dendritic cells.
  • the antibody may bind to dendritic cells located in the thymus of an individual.
  • the antibody may recognize any antigen derived from langerin, DEC-205, IL-2 receptor, CD25, CD 122, CLEC9A or a combination thereof.
  • the compositions comprises one or more antibodies fused with another molecule.
  • the antibody may be any antibody described herein, including an antibody that recognizes dendritic cells or markers of dendritic cells.
  • the antibody may be fused to any molecule, including a peptide of any length, a lipid of any length, a nucleic acid of any length, a small molecule, or a combination thereof.
  • the molecule fused to the antibody may comprise an antigen, including any antigen involved in an autoimmune disease.
  • the antigen may be represented by a peptide as a fragment of the antigen.
  • the molecule fused to the antibody may comprise an antigen derived from any protein including insulin, IL2, chromogranin A, glutamic acid decarboxylase 65 (GAD-65), IA-2, ZnT8, ICA69, IGRP, myelin oligodendrocyte glycoprotein (MOG), neurofilament NF-M, myelin basic protein (MBP), proteolipid protein (PLP), myelin-associated antigen (MAG), myelin-associated oligodendrocyte basic protein (MOBP), SlOOp, CNPase, Transaldolase, collagen basement membrane type IV, ANA, SMA, LKM-l, LKM-2, LKM-3, SLA, p62,spl00, M2, SSA, HLA-DR52a, BP-l, BP-2, IL-2, IFN-gamma, COL7A1, desmoglein-3, NALP-l RER, PTPN22, LPP, IL2RA,
  • the molecule fused to the antibody may comprise any antigen from insulin, including insulin B:9-23, insulin B:9-23 (R22E).
  • the molecule fused to the antibody may comprise any antigen from chromogranin A, including WE 14.
  • the molecule fused to the antibody may comprise any antigen from any fragment of a fusion between two or more proteins, such as the peptide 2.5HIP.
  • the molecule fused to the antibody may be any functional or natural variant of the antigens described herein.
  • the functional variant may have at least 80, 85, 90, 95, 96, 97, 98, or 99% identity thereof.
  • the composition may comprise a mixture of antibodies described herein.
  • the composition may comprise a mixture of antibodies fused with another molecule, including any of the antibodies fused with another molecule described herein.
  • the antibody may be fused to the molecule in any manner known in the art.
  • the antibody may be fused to the molecule using one or more covalent linkers, noncovalent linkers, cleavable linkers, or a combination thereof.
  • the noncovalent linker system may be the dockerin/cohesin system system.
  • a dockerin molecule may be linked to the antibody or the peptide.
  • a cohesin molecule may be linked to the antibody or the peptide.
  • an antibody is linked to a dockerin molecule and a peptide is linked to a cohesin molecule
  • composition according to the disclosure may be formulated for delivery via any route of administration.
  • Route of administration may refer to any systemic or local administration pathway known in the art, including but not limited to aerosol, nasal, oral, intravenous, intramuscular, intraperitoneal, inhalation, transmucosal, transdermal, parenteral, implantable pump, continuous infusion, topical application, capsules and/or injections.
  • compositions according to the disclosure can also comprise any one of
  • “Pharmaceutically acceptable carrier” refers to a pharmaceutically acceptable material, composition, or vehicle that is involved in carrying or transporting a composition of interest from one tissue, organ, or portion of the body to another tissue, organ, or portion of the body.
  • the carrier may be a liquid or solid filler, diluent, excipient, solvent, or encapsulating material, or a combination thereof.
  • Each component of the carrier must be “pharmaceutically acceptable” in that it must be compatible with the other ingredients of the formulation. It must also be suitable for use in contact with any tissues or organs with which it may come in contact, meaning that it must not carry a risk of toxicity, irritation, allergic response, immunogenicity, or any other complication that excessively outweighs its therapeutic benefits.
  • compositions according to the disclosure can also be encapsulated, tableted or prepared in an emulsion or syrup for oral administration. They can be encased in a syringe for injection.
  • Pharmaceutically acceptable solid or liquid carriers may be added to enhance or stabilize the composition, or to facilitate preparation of the composition.
  • Liquid carriers include syrup, peanut oil, olive oil, glycerin, saline, alcohols and water.
  • Solid carriers include starch, lactose, calcium sulfate, dihydrate, terra alba, magnesium stearate or stearic acid, talc, pectin, acacia, agar or gelatin.
  • the carrier may also include a sustained release material such as glyceryl monostearate or glyceryl distearate, alone or with a wax.
  • compositions may be made following the conventional techniques of pharmacy involving milling, mixing, granulation, and compressing, when necessary, for tablet forms; or milling, mixing and filling for hard gelatin capsule forms.
  • a liquid carrier When a liquid carrier is used, the preparation will be in the form of syrup, elixir, emulsion or an aqueous or non-aqueous suspension.
  • Such a liquid formulation may be administered directly or filled into a soft gelatin capsule.
  • Embodiments of the disclosure concern methods for administering one or more compositions described herein to an individual having, or at risk of having, an autoimmune disease.
  • the individual may have, or be at risk of having, Type 1 diabetes, rheumatoid arthritis, systemic lupus erythematosus, celiac sprue disease, pernicious anemia, vitiligo, scleroderma, psoriasis, Inflammatory bowel diseases, Addison’s Disease, Graves’ Disease, Sjogren’s syndrome, or any other autoimmune disease, or a combination thereof.
  • the individual may be any age such as an individual in utero, a neonatal individual, a pre-pubescent individual, a pubescent individual, or an adult.
  • a neonatal individual may be less than 1 month old, less than 2 months old, less than 3 months old, less than 4 months old, less than 5 months old, or less than 6 months old.
  • composition may be delivered using any acceptable route of administration either systemically or locally, including but not limited to aerosol administration, nasal administration, oral administration, intravenous administration, intramuscular administration, intraperitoneal administration, inhalation administration, transmucosal administration, transdermal administration, parenteral administration, implantable pump, continuous infusion, topical application, capsules and/or injections.
  • routes of administration either systemically or locally, including but not limited to aerosol administration, nasal administration, oral administration, intravenous administration, intramuscular administration, intraperitoneal administration, inhalation administration, transmucosal administration, transdermal administration, parenteral administration, implantable pump, continuous infusion, topical application, capsules and/or injections.
  • the individual described herein may be of any age, including an individual in utero, a neonatal individual, a pre-pubescent individual, a pubescent individual, or an adult.
  • the individual may receive one administration of at least one of the compositions described herein, or the individual may receive more than one administration of at least one of the compositions described herein.
  • the compositions may be administered to the individual at any frequency including, but not limited to, daily, weekly, monthly, annually, or any other prescribed frequency.
  • the composition may administered to the individual at various times not set by a specific frequency.
  • compositions according to the disclosure may be administered in a therapeutically effective amount.
  • the precise therapeutically effective amount is that amount of the composition that will yield the most effective results in terms of efficacy of treatment in a given subject. This amount will vary depending upon a variety of factors, including but not limited to the characteristics of the therapeutic compound (including activity, pharmacokinetics, pharmacodynamics, and bioavailability), the physiological condition of the subject (including age, sex, disease type and stage, general physical condition, responsiveness to a given dosage, and type of medication), the nature of the pharmaceutically acceptable carrier or carriers in the formulation, and the route of administration.
  • the composition is administered in combination with one or more compositions effective for ameliorating symptoms or causes of one or more autoimmune diseases.
  • the compositions effective for ameliorating symptoms or causes of one or more autoimmune diseases may comprise, for example, a steroid (including corticosteroids), a non steroid anti-inflammatory drug, insulin (or derivatives of insulin), an immune suppressing composition, a pain-killer, an anti-histamine, a biologic, or a combination thereof.
  • any of the cellular and/or non-cellular compositions described herein or similar thereto may be comprised in a kit.
  • one or more reagents for use in methods for preparing cellular or antibody therapies may be comprised in a kit.
  • Such reagents may include cells, such as dendritic cells and/or cells capable of producing antibodies, antigens, linkers, or a combination thereof, including the antibodies, antigens, and linkers disclosed herein; vectors encoding one or more antibodies, antigens, linkers, or a combination thereof, including antibodies, antigens, and linkers disclosed herein; nucleic acid or polypeptide components that allow production of one or more antibodies, antigens, linkers, or a combination thereof or a region thereof, including antibodies and antigens disclosed herein; one or more growth factors; one or more costimulatory factors; media; enzymes; buffers; nucleotides; salts; primers; and so forth.
  • the kit components are provided in suitable container means.
  • kits may be packaged either in aqueous media or in lyophilized form.
  • the container means of the kits will generally include at least one vial, test tube, flask, bottle, syringe or other container means, into which a component may be placed, and preferably, suitably aliquoted. Where there are more than one component in the kit, the kit also will generally contain a second, third or other additional container into which the additional components may be separately placed. However, various combinations of components may be comprised in a vial.
  • the kits of the present disclosure also will typically include a means for containing the components in close confinement for commercial sale. Such containers may include injection or blow molded plastic containers into which the desired vials are retained.
  • the liquid solution is an aqueous solution, with a sterile aqueous solution being particularly useful.
  • the container means may itself be a syringe, pipette, and/or other such like apparatus, or may be a substrate with multiple compartments for a desired reaction.
  • kits may be provided as dried powder(s).
  • the powder can be reconstituted by the addition of a suitable solvent. It is envisioned that the solvent may also be provided in another container means.
  • the kits may also comprise a second container means for containing a sterile acceptable buffer and/or other diluent.
  • reagents and materials include primers for amplifying desired sequences, nucleotides, suitable buffers or buffer reagents, salt, and so forth, and in some cases the reagents include apparatus or reagents for isolation of a particular desired cell(s).
  • the kit suitable for extracting one or more samples from an individual.
  • the apparatus may be a syringe, fine needles, scalpel, and so forth.
  • the targeted delivery (skin administration,
  • intraperitoneal or intraveneous) of peptides may alter the development and function of pathogenic T cells or protective T regulatory cells during neonatal development and halt the initiation of autoimmune Type 1 Diabetes.
  • PTM post-translationally modified
  • An example method for targeted deliver of peptides for altering the development and function of pathogenic T cells is therapeutically targeting dendritic cells by injecting anti- DEC-205 or anti-Langerin antibodies linked to pancreatic beta cell peptides such as, insulin B:9- 23 (partial agonist) peptide, insulin mimetope (R22E-agonist) (26), WE 14 or 2.5HIP to target the deletion of pathogenic T cells or the development of protective T regulatory cells.
  • pancreatic beta cell peptides such as, insulin B:9- 23 (partial agonist) peptide, insulin mimetope (R22E-agonist) (26), WE 14 or 2.5HIP to target the deletion of pathogenic T cells or the development of protective T regulatory cells.
  • modified b cell peptides to favor anti-inflammatory Tregs and delete b cell-destructive T effector cells.
  • This particular approach calls for the use of specific antibodies targeting dendritic cells (anti-Langerin and/or anti-DEC205) throughout neonatal/perinatal period of life.
  • the antibodies could be linked to various peptides specific for the pancreatic beta cell antigens targeted during autoimmune destruction.
  • the antibody-peptide product will be delivered on the skin or by intraperitoneal injection throughout the perinatal period of development as a vaccine.
  • Antigen availability drives central tolerance and antigen specific T regulatory (Treg) cell development in the thymus.
  • Insulin 2 -/-mice do not express insulin antigen in the thymus, which allows for escape of pathogenic auto reactive T cells and destruction of insulin producing beta cells, initiating Type 1 Diabetes.
  • Dendritic Cell (DC) transfer of B:9-23 or B:9-23(R22E) peptide pulsed cells into adult TCR transgenic significantly increases the number and ratio of thymic Tregs.
  • DC transfer of B:9-23(R22E) peptide pulsed cells into neonatal mice (wild type and TCR transgenic) significantly increased thymic Treg numbers and ratios.
  • Chromogranin A is the only other beta cell protein (antigen) known to be implicated in the onset of T cell specific T1D autoimmunity.
  • the antigenic peptide was found to be a fusion of insulin and chromogranin A, called hybrid insulin peptide (2.5HIP, Thomas Delong, Science 2016).
  • the fusion occurs from posttranslational modifications to Chromogranin A in beta cell granules.
  • the role of this peptide in the development of 2.5HIP specific T cells is unknown. DC transfer of 2.5HIP into neonatal mice (wild type and TCR transgenic) significantly increased thymic Treg number and ratios.
  • the advantages of this method would be that the antibody-peptide will reach more DCs that are located in the thymus than the number of peptide pulsed DCs that one can transfer and migrate to the thymus.
  • Insulin B 9-23(R22E)
  • Type 1 Diabetes is a T cell-mediated autoimmune disease that involves the destruction of insulin producing b cells found within the pancreatic islets of Langerhans.
  • T1D Type 1 Diabetes
  • DCs peripheral dendritic cells
  • Tregs neonatal b cell antigen specific CD4+ regulatory T cells
  • PTM post-translational modification
  • Pathogenic T cells that are specific for neo-antigens uniquely expressed in the pancreas may escape thymic selection. Therefore, one can utilize two experimental designs to test the role of peripheral antigen exposure on neonatal development of b cell specific Tregs.
  • Antibodies fused to antigens are useful for treating autoimmune diseases.
  • One antigen fused antibody system that was shown effective is an antibody that targets anti-Langerin fused to 2.5HIP using the non-covalent dockerin/ cohesin fusion system (referred to as a- Langerin-2.5HIP).
  • a- Langerin-2.5HIP the non-covalent dockerin/ cohesin fusion system
  • FIG 1 left side
  • adult NOD WT mice were intraperitoneal injected once with 3.0ug of a-Langerin APC.
  • thymus from the injected mice were harvested and co-stained with anti-Langerin PE to determine binding efficiency and persistence, in vivo , of the injected anti-Langerin antibody within the thymus over time (FIG 1, right side).
  • Neonatal BDC2.5 TCR Transgenic mice were intraperitoneal injected once with 5 pg anti-langerin alone, 2.5 pg a-Langerin-2.5HIP or 5 pg a- Langerin-2.5HIP (FIG 4, top) (bottom left) It appears 5 pg of a-Langerin-2.5HIP does not induce dramatic CD4+CD8+ DP reduction like adult mice with 10 pg. (right side) After 48 hours, CD4 SP Foxp3+ Treg development was assessed and significant increase is observed.
  • a-Langerin-2.5HIP treatment induces differential CD25 expression on thymic Tregs.
  • Day 1-3 Neonatal BDC2.5 TCR transgenic mice were intraperitoneal injected once with 2.5 pg a-Langerin-2.5HIP.“New” Foxp3 Tregs that are not CD25+ were seen (FIG 5).
  • Thymic Tregs are typically 50-60% CD25+ and peripheral Foxp3+ Tregs are near 90% positive in the periphery.
  • FIG 9 One experimental procedure (FIG 9), shows that a-Langerin-2.5HIP with IL-2 complex promotes thymocyte survival.
  • Day 2 Neonatal BDC2.5 TCR transgenic mice were intraperitoneal injected once with anti-langerin alone (FIG 10, upper left), 2.5 pg a-Langerin- 2.5HIP, or with anti-Langerin bound to active human IL-2 (FIG 10, upper second from left and upper middle respectively), or co-injected with mouse IL-2 bound to anti-CD25 (FIG 10, upper second from right) or anti-CD 122 and anti-CD25 (FIG 10, upper right).
  • IL-2 treatment with a- Langerin-2.5HIP treatment stabilizes CD4+CD8+ thymocyte development, while dramatically increasing Treg development (FIG 11) but does not rescue CD25 expression on“new” Foxp3+ Tregs (FIG 12).
  • 1-2 day old NOD WT female pups were injected with anti- langerin alone or a-Langerin-2.5HIP.
  • Diabetes incidence were monitored weekly by Diastix and confirmed by blood glucose level (FIG 13). Diabetes is defined as blood glucose level of >300 mg/dl for 2 consecutive days or >400 mg/dl at the first reading.
  • Foxp3+ Tregs are not killed by antibody treatment as indicate by cleaved (active) Caspase3 staining.
  • Day 2 Neonatal BDC2.5 TCR transgenic mice were intraperitoneal injected once with 2.5 pg anti-langerin alone, 2.5 pg a-Langerin-2.5HIP or DPBS.
  • a-Langerin-2.5HIP or anti-langerin alone does not kill“new” Foxp3+ Tregs (FIG 14).
  • a-Langerin-2.5HIP generated Foxp3+ cells are almost entirely CD73- (thymically derived) (FIG 15). Lack of CD73 expression indicates thymically derived Tregs.
  • Peripheral Tregs that circulate back to the thymus are CD73+.
  • Chromogranin A is a T cell antigen in human type 1 diabetes. Journal of autoimmunity 50: 38-41.
  • Islet beta-cell endoplasmic reticulum stress precedes the onset of type 1 diabetes in the nonobese diabetic mouse model. Diabetes 61: 818-827.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Diabetes (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Des modes de réalisation de l'invention concernent des procédés et des compositions associés à la prévention ou au retardement de l'apparition d'une maladie auto-immune, comprenant au moins le diabète de type I. Dans des modes de réalisation spécifiques, des procédés et des compositions sont associés à (a) un anticorps qui cible des cellules dendritiques et/ou des cellules Foxp3+ ; lié à (b) un peptide ou une fusion de peptides, les peptides étant des antigènes de cellules bêta pancréatiques ou étant un peptide dérivé d'un antigène auto-immun.
PCT/US2019/038264 2018-06-22 2019-06-20 Immunothérapie à base de peptide lié à un anticorps pour le diabète de type 1 Ceased WO2019246408A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862688468P 2018-06-22 2018-06-22
US62/688,468 2018-06-22

Publications (2)

Publication Number Publication Date
WO2019246408A2 true WO2019246408A2 (fr) 2019-12-26
WO2019246408A3 WO2019246408A3 (fr) 2020-02-06

Family

ID=68984308

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2019/038264 Ceased WO2019246408A2 (fr) 2018-06-22 2019-06-20 Immunothérapie à base de peptide lié à un anticorps pour le diabète de type 1

Country Status (1)

Country Link
WO (1) WO2019246408A2 (fr)

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070172453A1 (en) * 2002-08-30 2007-07-26 Vincent Geenen Tolerogenic approach for type 1 diabetes
NZ542134A (en) * 2003-03-04 2009-06-26 Alexion Pharma Inc Method of treating autoimmune disease by inducing antigen presentation by tolerance inducing antigen presenting cells
WO2016131911A1 (fr) * 2015-02-19 2016-08-25 INSERM (Institut National de la Santé et de la Recherche Médicale) Procédés de diagnostic et de traitement du diabète de type i

Also Published As

Publication number Publication date
WO2019246408A3 (fr) 2020-02-06

Similar Documents

Publication Publication Date Title
US20240122864A1 (en) Particles encapsulating fusion proteins containing linked epitopes
JP7007335B2 (ja) ペプチドコンジュゲート粒子
JP6557140B2 (ja) ペプチドコンジュゲート粒子
US20150150996A1 (en) Compositions and methods for antigen-specific tolerance
AU2016379413A1 (en) Covalent polymer-antigen conjugated particles
KR102808155B1 (ko) 면역 반응 조절용 탄수화물-개질 입자 및 미립자 제제
TW201039843A (en) Compositions and methods for induced tolerance
Kontos et al. Engineering antigen-specific immunological tolerance
US20220175896A1 (en) Methods and pharmaceutical compositions for inducing immune tolerance by mucosal vaccination with fc-coupled antigens
WO2021231898A2 (fr) Compositions de nanoparticules et leurs utilisations
Clemente-Casares et al. Antigen-specific therapeutic approaches in Type 1 diabetes
Nicholas et al. Autoantigen based vaccines for type 1 diabetes
Li et al. Enhancing antigen presentation and inducing antigen-specific immune tolerance with amphiphilic peptides
CA2882553A1 (fr) Preparation pour la prevention ou le traitement du diabete de type 1
WO2019246408A2 (fr) Immunothérapie à base de peptide lié à un anticorps pour le diabète de type 1
JP2025506717A (ja) 腫瘍内注射酵母ワクチン
WO2016066618A2 (fr) Compositions et méthodes de tolérance spécifique à des antigènes
JP2022537920A (ja) 改良されたワクチン製剤
EP2674168A1 (fr) Modulation des réponses des lymphocytes T d'effecteur par déplétion locale du composant complément C3

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 19823043

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 19823043

Country of ref document: EP

Kind code of ref document: A2